Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459607 | 0.84 | ERN1 (0.50) | CYP11B1CYP11B2ERN1CYP2A6 | |
| SCHEMBL15363645 | 0.79 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL15363795 | 0.74 | CYP11B1 (0.36) | CYP11B1CYP11B2PTGS2 | |
| SCHEMBL5666 | 0.73 | ALDH1A1 (0.53) | ALDH1A1KDM4EGAA | |
| SCHEMBL457062 | 0.72 | TGFBR1 (0.38) | ERN1PTGS2CCR1CCR5CCR8 | |
| SCHEMBL15363839 | 0.72 | CYP11B2 (0.39) | CYP11B1CYP11B2ERN1EPRS1 | |
| SCHEMBL16712451 | 0.68 | CYP11B1 (0.34) | CYP11B1CYP11B2PTGS2CYP2A6KDM4E | |
| SCHEMBL15363840 | 0.66 | ERN1 (0.33) | CYP11B1CYP11B2ERN1CYP2A6 | |
| SCHEMBL457853 | 0.64 | CYP2A6 (0.47) | ERN1CYP2A6KDM4E | |
| SCHEMBL456610 | 0.62 | ERN1 (0.53) | CYP11B1CYP11B2ERN1PTGS2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | CYP11B1 3708/4885CYP11B2 3986/4885ERN1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.